Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorFoo, S Sen
dc.contributor.authorMitchell, Paul L Ren
dc.contributor.authorBerlangieri, Salvatore Uen
dc.contributor.authorSmith, C Len
dc.contributor.authorScott, Andrew Men
dc.identifier.citationInternal Medicine Journal; 34(7): 388-97en
dc.description.abstractThe detection of lymphoma by computed tomography (CT) scanning is known to be improved by positron emission tomography (PET) and/or gallium scanning, although the direct comparative accuracy of these imaging modalities remains a subject of ongoing review.The aim of the present study was to compare PET scanning with conventional imaging (CT and/or gallium scanning) in patients with lymphoma.A retrospective study of 38 patients (25 men; 13 women; median age 39.5 years; range 18.0-81.0 years) who had had PET scans (24 scans at initial staging and 46 scans at restaging, including suspected disease relapse) was carried out. Thirty-one concurrent gallium scans had been performed. Disease was validated with clinical follow up or biopsy.The sensitivities of PET and CT at initial staging were 96 and 71%, respectively. PET identified additional sites of disease compared with CT in 29% of patients. Of the 15 patients who had had all three imaging modalities, the sensitivities of PET, CT and gallium were 93, 67 and 87%, respectively. At treatment completion, the positive predictive values of PET, CT and gallium scans for relapse given a residual mass were 100, 33 and 0%, respectively (P = 0.006 for PET and CT comparison). The negative predictive values of PET, CT and gallium were 76, 0 and 70%, respectively (P-value not significant). In suspected disease relapse, PET results changed management in 50% of patients.Compared with CT and gallium scans, PET has superior accuracy in staging and restaging, and its greatest value lies in its positive predictive value for relapse in patients with residual masses.en
dc.subject.otherAged, 80 and overen
dc.subject.otherCohort Studiesen
dc.subject.otherGallium Radioisotopes.diagnostic useen
dc.subject.otherHodgkin Disease.pathology.radiography.radionuclide imagingen
dc.subject.otherLymphoma, Non-Hodgkin.pathology.radiography.radionuclide imagingen
dc.subject.otherMiddle Ageden
dc.subject.otherPositron-Emission Tomographyen
dc.subject.otherReference Standardsen
dc.subject.otherRetrospective Studiesen
dc.subject.otherRisk Assessmenten
dc.subject.otherSensitivity and Specificityen
dc.subject.otherSeverity of Illness Indexen
dc.subject.otherTomography, X-Ray Computeden
dc.titlePositron emission tomography scanning in the assessment of patients with lymphoma.en
dc.typeJournal Articleen
dc.identifier.journaltitleInternal Medicine Journalen
dc.identifier.affiliationDepartment of Medical Oncology, Ludwig Institute for Cancer Research, University of Melbourne, Austin Hospital, Melbourne, Victoria, Australiaen
dc.type.austinJournal Articleen
item.fulltextNo Fulltext-
item.openairetypeJournal Article- Oncology- Newton-John Cancer Wellness and Research Centre- Haematology- Newton-John Cancer Wellness and Research Centre- Imaging and Therapy- Newton-John Cancer Research Institute-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

checked on Feb 3, 2023

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.